KRT6A (Keratin 6A)

Beyond oncology, mutations in KRT6A underlie pachyonychia congenita, and its dysregulation contributes to epidermal hyperproliferative disorders such as psoriasis. Overall, systematic elucidation of the structure-function-pathway-clinical axis of KRT6A offers new opportunities for precision medicine and supports its potential as a therapeutic target in cancer management.

These findings offer preliminary clues for future risankizumab-based combination strategies in psoriasis.

Functional assays using IL13RA1 and IL4R knockdown confirmed that IL-13 signaling promotes keratinocyte proliferation and migration. These findings define a key immunoregulatory pathway linking epithelial transformation and immune interaction, providing a cellular framework for understanding early cSCC development and identifying potential targets for intervention.

The 4 MRGs may contribute to the understanding on UPRmt in LUAD and the development of relevant medicine in clinical practice.

zDHHCs-mediated palmitoylation and its regulatory gene network critically shape pancreatic cancer heterogeneity, immune microenvironment, and prognosis. The PRGS model provides a novel molecular tool for patient stratification and may inform the development of precision therapies targeting palmitoylation-driven pathways in PC.

High-risk tumors owned shorter overall survival time, but were suitable for treatment with docetaxel and several small-molecule agents (MK-0752, BRD-K33199242, IC-87114, fumonisin B1, ilomastat, GW-788388, afobazole, and batimastat). Experimentally, inhibition of FAM129B effectively attenuated proliferative and aggressive phenotypes of TNBC cells. Collectively, our findings proposed the exosome-based gene signature for accurate estimation of clinical outcomes and assisting in individually tailoring therapies in TNBC as well as discovered FAM129B as a potential therapeutic target.

A stacked ensemble learning approach integrating all three modalities achieved superior performance, with an accuracy of 0.97 and an AUC of 0.99. In summary, our results demonstrate that combining single-cell transcriptomics and radiomics through ensemble deep learning enables accurate prediction of immunotherapy response in NSCLC, and identifies six DC-associated marker genes with potential as prognostic biomarkers.

A prognostic signature composed of CDCP1, CLIC6, FURIN, KRT6A, MFI2, and P2RY13, based on PANR-DEGs, provides a theoretical framework and reference for further LUAD research.

In addition, bioinformatics analysis and immunohistochemistry experiments verified that KRT6A mRNA and protein were up-regulated in LUAD, and could promote the development process of LUAD by promoting processes such as epidermis development, intermediate filament cytoskeleton and cornified envelope. This is the first pan-cancer analysis of KRT6A, which provides a comprehensive and systematic understanding of its role in various human tumors, and also reveals that KRT6A is expected to become a potential prognostic biomarker and a new target for cancer immunotherapy.

This study identifies GBP4-related prognostic genes and demonstrates the role of GBP4 in pancreatic cancer progression, providing new perspectives for prognostic prediction and therapeutic targeting.

These findings offer novel insights into resistance mechanisms and propose actionable strategies for integrating targeted and immunotherapies to improve outcomes for NSCLC patients. Future experimental and clinical studies are essential to validate and translate these findings into therapeutic advances.

Finally, several hub genes demonstrated favorable druggable potential for immunotherapy. Through integrated meta-analysis, this study identifies transcriptional, immunological, and structural pathways to melanoma metastasis and highlights keratin family genes as promising biomarkers for therapeutic targeting.